This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kinchington, P. R. Articles by Turse, S. E. Search for Related Content PubMed PubMed Citation Articles by Kinchington, P. R. Articles by Turse, S. E.

NEUROLOGY 1995;45:S13-S14
© 1995 American Academy of Neurology

Molecular basis for a geographic variation of varicella-zoster virus recognized by a peptide antibody

Paul R. Kinchington, PhD and Stephanie E. Turse, BS

From the Departments of Ophthalmology and Molecular Genetics and Biochemistry, University of Pittsburgh, PA.
Supported by Public Health Service grant EY 09397, a CORE Grant for Vision Research (EY 08098), and a Basil O'Connor Research Scholar Award from the March of Dimes Birth Defects Foundation.
Address correspondence and reprint requests to Dr. Paul R. Kinchington, Department of Ophthalmology, 1020 Eye and Ear Institute, University of Pittsburgh, 203 Lothrop Street, Pittsburgh, PA 15213.

A live attenuated varicella vaccine, derived from a Japanese isolate, is currently being widely used to modulate disease caused by varicella-zoster virus. Differentiation of the vaccine from wild-type isolates has been and will continue to be critical in the assessment of the vaccine in the United States. This has largely relied upon identification of characteristic DNA polymorphisms in the vaccine strain. In this report, we describe the identification of a new sequence polymorphism, located in the N-terminal coding sequence of open reading frame (ORF) 10. This variation results in the synthesis of an ORF 10 protein that is differentially recognized by antibodies to an ORF 10 synthetic peptide. The variation appears to be completely restricted to Japanese strains, including that used for the live attenuated varicella vaccine. As such, this polymorphism and the antibodies that differentially recognize it could prove highly useful in the assessment of the Japanese vaccine in the United States.

NEUROLOGY 1995;45(Suppl 8): S13-S14

This article has been cited by other articles:

				V. N. Loparev, A. Gonzalez, M. Deleon-Carnes, G. Tipples, H. Fickenscher, E. G. Torfason, and D. S. Schmid Global Identification of Three Major Genotypes of Varicella-Zoster Virus: Longitudinal Clustering and Strategies for Genotyping J. Virol., August 1, 2004; 78(15): 8349 - 8358. [Abstract] [Full Text] [PDF]

				R. J. Cohrs, D. H. Gilden, P. R. Kinchington, E. Grinfeld, and P. G. E. Kennedy Varicella-Zoster Virus Gene 66 Transcription and Translation in Latently Infected Human Ganglia J. Virol., June 15, 2003; 77(12): 6660 - 6665. [Abstract] [Full Text] [PDF]

				S. K. Danoff, M. E. Grasso, P. B. Terry, and J. A. Flynn Pleuropulmonary Disease Due to Pergolide Use for Restless Legs Syndrome Chest, July 1, 2001; 120(1): 313 - 316. [Abstract] [Full Text] [PDF]

				A Münchau and K P Bhatia Pharmacological treatment of Parkinson's disease Postgrad. Med. J., October 1, 2000; 76(900): 602 - 610. [Full Text]

				D J BROOKS Dopamine agonists: their role in the treatment of Parkinson's disease J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 685 - 689. [Full Text] [PDF]

				C. Grose Varicella-Zoster Virus: Less Immutable Than Once Thought Pediatrics, May 1, 1999; 103(5): 1027 - 1028. [Full Text]